Article Per Year (5 Year)
p-Index From 2021 - 2026
0.702
P-Index
This Author published in this journals
All Journal Indonesian Journal of Global Health Research
Anak Agung Istri Saraswati Dewi
Mangusada Regional General Hospital

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Oral Squamous Papilloma on Tongue: A Case Report Edison Febrianto; Made Hemina Laksmi; Anak Agung Ari Agung Kayika Silayukti; Tjokorda Istri Amrita Rosvanti; Anak Agung Istri Saraswati Dewi
Indonesian Journal of Global Health Research Vol. 8 No. 5 (2026): Indonesian Journal of Global Health Research
Publisher : GLOBAL HEALTH SCIENCE GROUP

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37287/ijghr.v8i5.2159

Abstract

Human papillomavirus (HPV) is the most common virus involved in sexually transmited disease. It is one of etiology in a variety of skin and mucosal disease. Squamous papilloma is the most common benign epithelial tumor in the oral cavity. It can occur at any age but mostly seen in third to fifth decades and it associated with HPV type 6 and 11 in approximately 50% cases. Gross description of the lesion can be like papillary (cauliflower-like), exophytic, and tan-white lesion. A 50-year old male with chief complaint of white cauliflower-like lesion on left side of his tongue. The lesion was a cauliflower-like white papule with a verrucous surface. Fully cauterized with a electrocauter. One week after the treatment patient came with great wound healing and no sign of new lesion appear. This case report  discuss about unique presentation of oral squamous papilloma, the main purpose is to help other clinicians to diagnose clinically even without advance tool. We encounter with the patient at outpatient clinic, the patient already been informed about the study and agreed that his case to be used in this study. One of most common benign epithelial tumour of oral mucosa is squamous papilloma. Defined as exophytic proliferation with finger-like projections. It is usually asymptomatic and detected through clinical examination by clinicians. The color depends on the degree of keratinization, there are variety of the color including red, pink, or white. The most common site for oral squamous papilloma is tongue, soft palate/uvula, lips, ginggiva, also may occur in oropharynx and larynx. The option for treatment in oral squamous papilloma is surgical excision. Oral squamous papilloma is a benign lesion of the oral cavity. It is presented as exophytic mases arising in the oral cavity and usually asymptomatic. Even though it is asymptomatic, early detection and management is important to prevent further growth.
The Great Imitator Meets Pruritic Papular Eruption: A Case of Secondary Syphilis and HIV Co-Infection Gede Yoga Utama Putra; Anak Agung Ari Agung Kayika Silayukti; Tjokorda Istri Amrita Rosvanti; Anak Agung Istri Saraswati Dewi; Made Hemina Laksmi
Indonesian Journal of Global Health Research Vol. 8 No. 5 (2026): Indonesian Journal of Global Health Research
Publisher : GLOBAL HEALTH SCIENCE GROUP

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37287/ijghr.v8i5.2379

Abstract

Secondary syphilis, notoriously known as "the great imitator," can present with highly atypical cutaneous manifestations, particularly in immunocompromised individuals. In patients with human immunodeficiency virus (HIV) co-infection, distinguishing secondary syphilis from HIV-associated dermatoses, such as pruritic papular eruption (PPE), poses a significant diagnostic challenge. This report aims to describe an atypical case of secondary syphilis mimicking PPE in a newly diagnosed HIV patient, to highlight the diagnostic complexities and the potential risks of inappropriate empiric systemic corticosteroid therapy. A 26-year-old male presented with a one-month history of a generalized, intensely pruritic, and crusted papular rash. His condition rapidly disseminated and worsened following empiric treatment with systemic corticosteroids by a general practitioner. Dermatological examination revealed generalized, well-demarcated erythematous papules with overlying crusts and fine scales, closely mimicking PPE. The patient reported a history of high-risk sexual behavior. Serological testing confirmed active secondary syphilis (VDRL 1:64, TPHA reactive) and revealed a previously undiagnosed HIV infection. The patient was successfully treated with a single dose of intramuscular benzathine penicillin G (2.4 million IU) and topical therapy comprising desoximetasone 0.25% and gentamicin 0.1% creams, alongside an immediate referral for antiretroviral therapy (ART). This case highlights the clinical overlap between atypical secondary syphilis and PPE in HIV-positive patients. It strongly underscores the critical need for comprehensive sexually transmitted infection (STI) screening prior to initiating systemic immunosuppressive therapy for generalized eruptions, especially in high-risk populations. 
The Role of Secukinumab in the Management of Moderate to Severe Psoroasis: A Systematic Review of Efficacy and Safety Ni Komang Sri Adelia Cahya Ningrum; Tjokorda Istri Amrita Rosvanti; Anak Agung Ari Agung Kayika Silayukti; Anak Agung Istri Saraswati Dewi; Made Hermina Laksmi
Indonesian Journal of Global Health Research Vol. 8 No. 5 (2026): Indonesian Journal of Global Health Research
Publisher : GLOBAL HEALTH SCIENCE GROUP

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37287/ijghr.v8i5.2384

Abstract

Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by erythematous, scaly plaques. In moderate to severe psoriasis, conventional therapies often provide a suboptimal response, making biologic therapies such as secukinumab an important treatment option. Secukinumab is a human IgG1κ monoclonal antibody that targets interleukin-17A (IL-17A). To assess the efficacy and safety of secukinumab in the management of moderate to severe psoriasis. This study is a systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search was conducted through PubMed, Scopus, the Cochrane Library, ScienceDirect, and Google Scholar through April 2026. Included studies were randomized controlled trials (RCTs) evaluating the efficacy and safety of secukinumab in moderate to severe psoriasis. Efficacy outcomes included the Psoriasis Area and Severity Index (PASI), Investigator Global Assessment (IGA), and Dermatology Life Quality Index (DLQI), while safety outcomes included adverse events and serious adverse events. Seven studies met the inclusion criteria. Overall, secukinumab demonstrated high efficacy in improving the clinical manifestations of psoriasis, with better PASI90 and PASI100 scores compared to comparator biologics such as ustekinumab. Secukinumab also provided a rapid clinical response and improved patients' quality of life. The most frequently reported adverse events included nasopharyngitis, upper respiratory tract infection, headache, and injection site reactions, while serious adverse events were reported in low numbers. Secukinumab is an effective and safe biologic therapy for moderate to severe psoriasis.
Efficacy and Safety of Anifrolumab in Patients with Cutaneous Lupus Erythematosus: A Systematic Review Gede Yoga Utama Putra; Anak Agung Ari Agung Kayika Silayukti; Tjokorda Istri Amrita Rosvanti; Anak Agung Istri Saraswati Dewi; Made Hemina Laksmi
Indonesian Journal of Global Health Research Vol. 8 No. 5 (2026): Indonesian Journal of Global Health Research
Publisher : GLOBAL HEALTH SCIENCE GROUP

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37287/ijghr.v8i5.2515

Abstract

Cutaneous lupus erythematosus (CLE) significantly impacts patient quality of life, and many cases remain refractory to standard-of-care treatments such as antimalarials and corticosteroids. Anifrolumab, a type I interferon receptor antagonist, has shown efficacy in systemic lupus erythematosus (SLE), but its specific impact on diverse CLE subtypes in real-world settings requires further synthesis. To systematically review the clinical efficacy, safety, and steroid-sparing potential of anifrolumab in patients with CLE. A systematic literature search was conducted across PubMed, ScienceDirect, and Cochrane Library for articles published between 2021 and 2026. From an initial yield of 217 articles, 5 studies reporting on anifrolumab treatment for CLE subtypes were ultimately included after rigorous screening. Data on clinical response, specifically the cutaneous lupus erythematosus disease area and severity index (CLASI) scores and onset of action, were extracted and synthesized. Five studies involving a total of 40 patients were included. The majority of patients had failed multiple prior therapies. Results consistently showed a rapid and significant decrease in CLASI activity scores, often within the first 4 to 12 weeks of aniflorumab treatment. Notably, one major cohort reported that 50% of patients were able to discontinue prednisone entirely. Efficacy was observed across various subtypes, including discoid lupus erythematosus (DLE) and subacute CLE (SCLE) cases. Adverse events were consistent with previously reported safety profiles. Real-world evidence suggests that anifrolumab is a potent and rapid-acting treatment for refractory CLE, offering significant clinical improvement and a vital steroid-sparing effect. These findings support its use in patients failing conventional therapies, though large-scale prospective trials specifically for CLE are warranted.
Co-Authors Anak Agung Ari Agung Kayika Silayukti Edison Febrianto Gede Yoga Utama Putra Made Hemina Laksmi Made Hermina Laksmi Ni Komang Sri Adelia Cahya Ningrum Tjokorda Istri Amrita Rosvanti